Antibiotic-resistant infections cost the US health care system over $20 billion annually

20 October 2009

An eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) in the USA, sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC), has been released by the Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H Stroger, Jr Hospital of Cook County).

The authors conducted an exhaustive chart-by-chart review of 1,391 patients hospitalized in the year 2000, 188 of which had ARIs (13.5%). The medical costs attributed to these ARIs ranged from $18,588 to $29,069 per patient, while the duration of hospital stay was extended 6.4 - 12.7 days for affected patients. Additionally, the excess mortality attributed to ARIs alone was 6.5% - a death rate two-fold higher than in patients without ARIs. The authors also estimated the societal costs incurred at this hospital as a result of the ARIs to be between $10.7 and $15 million, which is the cost that hits the families of those infected.

The study, titled "Hospital and Societal Costs of Antimicrobial Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship," analyzed the medical and human cost associated with ARIs. It was conducted at the Cook County (Stroger) Hospital of Chicago, Illinois. Several studies have looked at the medical costs of these infections, but this is the first to look at the cost to families as well.

"The findings indicate that significant health and economic benefits could be realized through effective interventions to reduce antimicrobial-resistant and healthcare-associated infections," according to Rebecca Roberts, Department of Emergency Medicine, Cook County (Stroger) Hospital and the lead study author.

"At a time when our country is debating how to deliver better, more affordable care, this study demonstrates the enormous cost savings that could be realized, for both the health care system and to individuals and their families. These costs will only continue to increase if we don't amend our behavior and practice a more prudent usage of antibiotics," said Stuart Levy, professor of medicine at Tufts University School of Medicine, a senior author of the paper and co-founder and president of the APUA, which initiated the study in accord with its mission to "preserve the power of antibiotics".

Extrapolating the costs nationwide

"The results offer some good insight regarding just how much ARIs are costing the nation: not just in terms of dollars, but human life and suffering," said Dr Levy. "As the enormous costs identified here are viewed on a national scale, it is clear that effectively addressing the issue of antimicrobial-resistant infection is an essential element for stemming the rising tide of healthcare costs in the USA. Further study is required, specifically to see how much we could save on a national level if we took some basic steps to halt the development of resistant infections and their spread within hospitals," Dr Levy said.

Dr Roberts explained: "If we apply the conservative costs seen in the Cook County (Stroger) Hospital study to all US hospital admissions in the year 2000 and apply the same selection criteria used in that study nationwide, there would have been nearly 900,000 cases of ARIs in the year 2000. By applying the range of additional costs seen in the Cook...study of $18,588 to $29,069 to this enormous number of ARIs, we could conceivably avoid $16.6 billion on the low end and up to $26 billion in additional health care costs stemming from the treatment of these preventable infections: "

Even a 20% reduction in these infections would save between $3.2 and $5.2 billion a year and between 5.7 and 11.3 million additional days in the hospital. Clearly, any discussion of health care reform must look at the cost of current clinical practice and the savings we could realize if we used antibiotics more prudently," noted Dr Roberts. "Imagine if these hospital beds and health care resources were used instead for preventive care or for under-served patients," she added.

"Assuming 900,000 ARI cases in the year 2000, based on the conservative selection criteria used in our study, the total societal costs of ARIs to U.S. households in the year 2000 was approximately $35 billion," Dr Roberts added. This includes lost wages from extended hospital stays and from premature deaths.

A study suggested by the late Senator Edward Kennedy

In discussions with the late Senator Edward M. Kennedy on the topic of drug resistance and health care, "I spoke frequently with Senator Kennedy about the avoidable costs from the misuse of antibiotics," Dr Levy said, adding: "Without fail, the Senator always concluded our discussions on the topic by telling me that we need to quantify the cost of treating antibiotic-resistant infections in order to make any real progress toward an appropriate policy for antibiotic stewardship. In a very real sense, this study grew from those talks with the late senator."

"This study is the first to quantify the alarming impact of antibiotic resistant infections on treatment costs and patient outcomes," said Herb Steward, general manager and executive vice president bioMerieux North America, which funded this study. "It also highlights the vital role of simple, rapid and cost effective diagnostics in order to get the right information to clinicians as fast as possible so they can treat patients appropriately and use antibiotics prudently, while improving care and patient outcomes and reining in unnecessary costs."

Societal impact more than just financial

"The societal financial impact of $15 million based on just over 188 cases of ARI is an alarming finding," said Robert Weinstein, interim chairman, Department of Medicine, Cook County (Stroger) Hospital, professor of Medicine at Rush University Medical College, and a senior author and initiator of the project at Cook County (Stroger) Hospital. "Sustaining these kinds of costs is simply not tenable for individual families and for the economy at large. With healthcare reform and the focus on the direct cost of care, this study should remind us that every dollar spent to treat avoidable illness ripples throughout society and has an impact on individual, family, community, and corporate budgets across the nation," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical